Oral Oncology Reports最新文献

筛选
英文 中文
Precision-directed therapy in salivary duct carcinoma 涎腺导管癌的精确定向治疗
Oral Oncology Reports Pub Date : 2025-05-15 DOI: 10.1016/j.oor.2025.100748
Shambhavi Singh , Irene George , Darshana Patil , Prashant Kumar , Rajan Datar , Vijay Haribhakti , Aditya Shreenivas , Sewanti Limaye
{"title":"Precision-directed therapy in salivary duct carcinoma","authors":"Shambhavi Singh ,&nbsp;Irene George ,&nbsp;Darshana Patil ,&nbsp;Prashant Kumar ,&nbsp;Rajan Datar ,&nbsp;Vijay Haribhakti ,&nbsp;Aditya Shreenivas ,&nbsp;Sewanti Limaye","doi":"10.1016/j.oor.2025.100748","DOIUrl":"10.1016/j.oor.2025.100748","url":null,"abstract":"<div><div>Salivary ductal carcinoma is a rare, aggressive salivary gland carcinoma with poor prognosis and high relapse rate. In recurrent metastatic cases, the median survival is only 5 months. Despite the treatment with multimodal therapeutic strategies, conventional treatments demonstrate a limited effect on long-term survival of the patients. In this study we report two cases of salivary ductal carcinoma patients managed with precision-directed, biomarker-guided therapeutic approaches. In the first case androgen receptor (AR) and HER2 positivity by immunohistochemistry analysis were detected. The patient was treated with AR directed targeted therapy enzalutamide and Leuprolide as maintenance therapy. Disease progression with an emergent HER2 expression by immunohistochemistry led to the inclusion of trastuzumab and pertuzumab. While in the second case the patient progressed on neoadjuvant chemotherapy and the subsequent molecular analysis revealed high expression of PD-L1 and was treated with pembrolizumab in combination with chemotherapy. Follow up assessment revealed treatment durable responses and disease control in both the patients. These cases underscore the potential role of comprehensive molecular profiling-guided personalised therapeutic approaches in the management of advanced SDC patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100748"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Association between dental exams and diagnosis of head and neck cancer” 对《口腔检查与头颈癌诊断的关系》一文的评论
Oral Oncology Reports Pub Date : 2025-05-13 DOI: 10.1016/j.oor.2025.100747
Palanivel Velmurugan, Vinayagam Mohanavel, Kanagasabapathy Sivasubramanian
{"title":"Comment on “Association between dental exams and diagnosis of head and neck cancer”","authors":"Palanivel Velmurugan,&nbsp;Vinayagam Mohanavel,&nbsp;Kanagasabapathy Sivasubramanian","doi":"10.1016/j.oor.2025.100747","DOIUrl":"10.1016/j.oor.2025.100747","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100747"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of recurrent oral carcinoma cuniculatum with immune checkpoint blockade: A case report and literature review 免疫检查点阻断治疗复发性口腔癌1例并文献复习
Oral Oncology Reports Pub Date : 2025-05-13 DOI: 10.1016/j.oor.2025.100746
William Jones , Azeem S. Kaka , Soumon Rudra , Daniel Lubin , Faisal Saeed , Kelly R. Magliocca , Nabil F. Saba , Nicole C. Schmitt
{"title":"Treatment of recurrent oral carcinoma cuniculatum with immune checkpoint blockade: A case report and literature review","authors":"William Jones ,&nbsp;Azeem S. Kaka ,&nbsp;Soumon Rudra ,&nbsp;Daniel Lubin ,&nbsp;Faisal Saeed ,&nbsp;Kelly R. Magliocca ,&nbsp;Nabil F. Saba ,&nbsp;Nicole C. Schmitt","doi":"10.1016/j.oor.2025.100746","DOIUrl":"10.1016/j.oor.2025.100746","url":null,"abstract":"<div><h3>Background</h3><div>Carcinoma cuniculatum (CC) is a rare variant of carcinoma that can arise in the oral cavity. CC can be locally aggressive but rarely metastasizes, and there are few reports of treatment with systemic therapy.</div></div><div><h3>Methods</h3><div>We present a case of a 44-year-old man with T4bN0 oral carcinoma cuniculatum of the retromolar trigone.</div></div><div><h3>Results</h3><div>Despite resection with wide margins and adjuvant radiation, the disease recurred 14 months later and was extensive. Following positive margins on a repeat resection, the patient opted for systemic therapy. Despite a PD-L1 combined positive score of 15, the patient did not respond to immunotherapy (pembrolizumab).</div></div><div><h3>Conclusion</h3><div>Though it has a low propensity for metastasis, oral CC is a locally aggressive variant of squamous cell carcinoma, and recurrences are difficult to treat. Although reports of systemic therapy for CC are limited, this case suggests that immunotherapy may have limited activity in this oral cancer variant.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100746"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-driven biomarker discovery for early diagnosis and prognosis in oral oncology 人工智能驱动的口腔肿瘤早期诊断和预后的生物标志物发现
Oral Oncology Reports Pub Date : 2025-05-09 DOI: 10.1016/j.oor.2025.100749
Suresh Munnangi, Satheeskumar R
{"title":"AI-driven biomarker discovery for early diagnosis and prognosis in oral oncology","authors":"Suresh Munnangi,&nbsp;Satheeskumar R","doi":"10.1016/j.oor.2025.100749","DOIUrl":"10.1016/j.oor.2025.100749","url":null,"abstract":"<div><div>This study presents an AI-powered multi-omics framework for early detection and prognosis of oral squamous cell carcinoma (OSCC), integrating genomic, transcriptomic, and proteomic data through advanced deep learning architectures. Analysing 1527 OSCC samples from TCGA and GEO databases, we developed a novel multimodal pipeline combining: (1) graph neural networks for heterogeneous data fusion, (2) LASSO regression for robust feature selection, and (3) explainable AI (SHAP, attention mechanisms) for clinical transparency. Our CNN-based diagnostic model demonstrated exceptional performance (accuracy: 93.2 %, 95 % CI: 91.4–94.7; sensitivity: 91.5 % for Stage I tumours; AUC: 0.96), significantly surpassing conventional histopathology (p &lt; 0.001). Three clinically validated biomarker panels were established: (i) a diagnostic panel (TP53/CDKN2A/EGFR, 94.1 % specificity), (ii) an HPV-associated prognostic panel (P16/RB1/E2F1), and (iii) a metastasis prediction panel (TWIST1/VIM/CDH1, C-index = 0.82). Prospective validation in 412 patients showed 43 % reduction in false negatives (15.2 %–8.7 %) with 82 % pathologist concordance. The modular platform addresses critical clinical needs: high-risk screening, therapeutic decision support, and intraoperative margin assessment. IRB-approved implementation confirms real-world viability, positioning this framework as a transformative tool for OSCC precision oncology.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100749"},"PeriodicalIF":0.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50 (Gy) in 20 study” “低分割辅助放疗治疗头颈部皮肤鳞状细胞癌和基底细胞癌:50 (Gy)在20项研究中的评论”
Oral Oncology Reports Pub Date : 2025-04-11 DOI: 10.1016/j.oor.2025.100739
Efsun Somay , Erkan Topkan , Ugur Selek
{"title":"Comment on “Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50 (Gy) in 20 study”","authors":"Efsun Somay ,&nbsp;Erkan Topkan ,&nbsp;Ugur Selek","doi":"10.1016/j.oor.2025.100739","DOIUrl":"10.1016/j.oor.2025.100739","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100739"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing efficacy and safety of weekly vs. triweekly cisplatin concurrently with radiotherapy for locally advanced head and neck cancer: Systematic review and meta-analysis 比较每周顺铂与三周顺铂联合放疗治疗局部晚期头颈癌的疗效和安全性:系统评价和荟萃分析
Oral Oncology Reports Pub Date : 2025-04-08 DOI: 10.1016/j.oor.2025.100738
Mohammed Amine Saâd , Imad Taleb , Sofia El Omri , Hamadoun Traoré , Imane Chahbounia , Choukri Elm'hadi , Saïda Lamine , Mohammed Anouar Mokhlis , Lamia Aalaoui , Mohamed Reda Khmamouche , Khaoula Alaoui Slimani , Yassir Sbitti , Tarik Mahfoud , Hassan Errihani , Mohamed Ichou , Rachid Tanz
{"title":"Comparing efficacy and safety of weekly vs. triweekly cisplatin concurrently with radiotherapy for locally advanced head and neck cancer: Systematic review and meta-analysis","authors":"Mohammed Amine Saâd ,&nbsp;Imad Taleb ,&nbsp;Sofia El Omri ,&nbsp;Hamadoun Traoré ,&nbsp;Imane Chahbounia ,&nbsp;Choukri Elm'hadi ,&nbsp;Saïda Lamine ,&nbsp;Mohammed Anouar Mokhlis ,&nbsp;Lamia Aalaoui ,&nbsp;Mohamed Reda Khmamouche ,&nbsp;Khaoula Alaoui Slimani ,&nbsp;Yassir Sbitti ,&nbsp;Tarik Mahfoud ,&nbsp;Hassan Errihani ,&nbsp;Mohamed Ichou ,&nbsp;Rachid Tanz","doi":"10.1016/j.oor.2025.100738","DOIUrl":"10.1016/j.oor.2025.100738","url":null,"abstract":"<div><h3>Background</h3><div>Cisplatin-based chemotherapy is widely used in the treatment of locally advanced head and neck cancer (HNC). The optimal dosing schedule, whether weekly or triweekly, has been a subject of debate. This study aims to evaluate the efficacy and safety of weekly versus triweekly cisplatin regimens in this patient population.</div></div><div><h3>Material and methods</h3><div>In accordance with the PRISMA guidelines, we conducted this meta-analysis to compare outcomes associated with weekly and triweekly cisplatin regimens. The endpoints examined were overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) and safety. This meta-analysis protocol was registered in PROSPERO (CRD42023461292).</div></div><div><h3>Results</h3><div>The analysis of survival outcomes demonstrated no difference between the two schedules in terms of OS, PFS, LRRFS and DMFS at 2 and 3 years and 5 years (except for 2 years LRRFS). The odds ratio of OS at 2 years was 1.02 (p = 0.87) at 3 years 0.90 (p = 0.46) and at 5 years 1.13 (p = 0.59), and for PFS at the OR 2 years was 0.97 (p = 0.85) at 3 years 0.87 (p = 0.30) and at 5 years 0.86 (p = 0.55). Triweekly was superior to weekly cisplatin in terms of short-term LRRFS (at 2 years), with an OR of 1.57 (p = 0.02). Both protocols were similar in terms of adverse events.</div></div><div><h3>Conclusion</h3><div>Both weekly and triweekly cisplatin regimens show comparable survival outcomes and safety profiles in patients with head and neck cancers, except for short term LRRFS (at 2 years). These findings suggest that treatment decisions should be tailored to the patient's individual profile, including comorbidities and tolerability. Future studies should explore cumulative dosing and biomarkers to refine treatment strategies further.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100738"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma 头颈部鳞状细胞癌患者放疗和化疗期间骨骼肌质量的变化及相关因素
Oral Oncology Reports Pub Date : 2025-03-28 DOI: 10.1016/j.oor.2025.100737
Anouk W.M.A. Schaeffers , Hannah A. Scholten , Annemieke Kok , Floris C.J. Reinders , Rebecca K. Stellato , Ernst J. Smid , Maartje A. van Beers , Carla H. van Gils , Caroline M. Speksnijder , Marielle P. Philippens , Lot A. Devriese , Remco de Bree
{"title":"Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma","authors":"Anouk W.M.A. Schaeffers ,&nbsp;Hannah A. Scholten ,&nbsp;Annemieke Kok ,&nbsp;Floris C.J. Reinders ,&nbsp;Rebecca K. Stellato ,&nbsp;Ernst J. Smid ,&nbsp;Maartje A. van Beers ,&nbsp;Carla H. van Gils ,&nbsp;Caroline M. Speksnijder ,&nbsp;Marielle P. Philippens ,&nbsp;Lot A. Devriese ,&nbsp;Remco de Bree","doi":"10.1016/j.oor.2025.100737","DOIUrl":"10.1016/j.oor.2025.100737","url":null,"abstract":"<div><h3>Background and purpose</h3><div>The aim is to investigate whether lumbar skeletal muscle index (LSMI) decreases during treatment of head and neck squamous cell carcinoma (HNSCC) patients, and which pre-treatment variables are associated with change.</div></div><div><h3>Materials and methods</h3><div>The LSMI before and during treatment was assessed using MRI scans of HNSCC patients treated with radiotherapy (RT) or chemoradiotherapy (CRT). Mixed models assessed LSMI change and pre-treatment covariates (i.e. age, BMI, tumor characteristics and treatment type).</div></div><div><h3>Results</h3><div>In 63 patients the LSMI decreased from 40.56 cm<sup>2</sup>/m<sup>2</sup> to 39.96 cm<sup>2</sup>/m<sup>2</sup> (<em>p</em> trend = 0.008) on average. The LSMI of CRT patients decreased more than the LSMI of RT patients, but this was not significant (40.85–39.63 cm<sup>2</sup>/m<sup>2</sup> vs. 40.37 to 40.19 cm<sup>2</sup>/m<sup>2</sup>; p-interaction = 0.052). No effects of pre-treatment covariates on the LSMI trend over time were observed.</div></div><div><h3>Conclusion</h3><div>LSMI decreased during treatment in HNSCC patients, which was not related to pre-treatment variables, but seemed slightly larger for CRT patients than RT patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100737"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sinonasal primary squamous cell carcinoma: A case report to illustrate key diagnostic and therapeutic considerations in managing sinonasal squamous cell carcinoma 鼻窦炎原发鳞状细胞癌:一个病例报告说明鼻窦炎鳞状细胞癌的诊断和治疗要点
Oral Oncology Reports Pub Date : 2025-03-26 DOI: 10.1016/j.oor.2025.100736
A.C. Drossaert , G.K.P. Bittermann , P.A.W.H. Kessler
{"title":"Sinonasal primary squamous cell carcinoma: A case report to illustrate key diagnostic and therapeutic considerations in managing sinonasal squamous cell carcinoma","authors":"A.C. Drossaert ,&nbsp;G.K.P. Bittermann ,&nbsp;P.A.W.H. Kessler","doi":"10.1016/j.oor.2025.100736","DOIUrl":"10.1016/j.oor.2025.100736","url":null,"abstract":"<div><div>Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy that affects the nasal cavity and paranasal sinuses, representing only 3 % of nasopharyngeal malignancies. It predominantly affects the maxillary sinus, with less frequent involvement of the ethmoid and sphenoid sinuses. SNSCC typically presents with nonspecific symptoms such as epistaxis, pain, and signs of ulceration, often leading to a delayed diagnosis. Due to its late presentation, aggressive nature, and potential for recurrence, SNSCC presents significant challenges in diagnosis and management. A representative clinical case is described to emphasize the importance of a multidisciplinary approach regarding the diagnosis and treatment in managing SNSCC.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100736"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering oral cancer subtypes: Integrating differential gene expression and pathway analysis followed by non-negative matrix factorization transcription analysis 解密口腔癌亚型:整合差异基因表达和通路分析,然后进行非负性基质因子化转录分析
Oral Oncology Reports Pub Date : 2025-03-24 DOI: 10.1016/j.oor.2025.100735
Anoop Kumar Tiwari , Devansh Jain , Jayesh Kumar Tiwari , Shyam Kishore , Akhilesh Kumar Singh , Sushant Kumar Shrivastava , Arun Khattri
{"title":"Deciphering oral cancer subtypes: Integrating differential gene expression and pathway analysis followed by non-negative matrix factorization transcription analysis","authors":"Anoop Kumar Tiwari ,&nbsp;Devansh Jain ,&nbsp;Jayesh Kumar Tiwari ,&nbsp;Shyam Kishore ,&nbsp;Akhilesh Kumar Singh ,&nbsp;Sushant Kumar Shrivastava ,&nbsp;Arun Khattri","doi":"10.1016/j.oor.2025.100735","DOIUrl":"10.1016/j.oor.2025.100735","url":null,"abstract":"<div><div>Oral cancer is a major public health concern around the globe, and its classification relies on factors such as habitual status and tumor stages. However, a significant gap exists in understanding oral cancer patients' molecular and genomic characteristics. This study aims to bridge this gap by analyzing International Cancer Genome Consortium (ICGC's) oral cancer data, which identified 2270 differentially expressed genes related to oral cancer. We employed pathway enrichment analysis, highlighting key pathways including hypoxia, VEGF, PI3K, and TGF-β, and STAT2, E2F4, and SP1 transcription factors enriched in tumor samples compared to normal samples. Moreover, we utilized a non-negative matrix factorization (NMF) technique for unsupervised subtype discovery and identified three distinct tumor subgroups. Each subgroup exhibited unique molecular profiles, with pathways related to TNF-α, NF-κB, and hypoxia enriched across all groups. Notably, transcription factor analysis revealed crucial differences: subgroup A was enriched in EGR1, TP53, and HIF1A; subgroup B showed high levels of CDX2 and HNF4A; while subgroup C was characterized by enrichment in ATF4 and E2F4. These findings suggest the feasibility of classifying oral squamous cell carcinoma (OSCC) patients based on gene expression profiles, laying a foundational framework for future research aimed at personalized treatment strategies.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100735"},"PeriodicalIF":0.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Swallowing function, body image and uncertainty in illness after reconstruction in oral cancer survivors 口腔癌幸存者重建后的吞咽功能、身体形象和疾病的不确定性
Oral Oncology Reports Pub Date : 2025-03-17 DOI: 10.1016/j.oor.2025.100734
Chen-Chan Kuo , Shiu-Yu C. Katie Lee , Chun-Ta Liao
{"title":"Swallowing function, body image and uncertainty in illness after reconstruction in oral cancer survivors","authors":"Chen-Chan Kuo ,&nbsp;Shiu-Yu C. Katie Lee ,&nbsp;Chun-Ta Liao","doi":"10.1016/j.oor.2025.100734","DOIUrl":"10.1016/j.oor.2025.100734","url":null,"abstract":"<div><h3>Background</h3><div>Swallowing and body image are the main concerns after reconstruction for oral cancer. Perceiving uncertainty or an unpredictable future is a significant psychosocial stressor in cancer survivors. This study aimed to explore swallowing function, body image, and uncertainty after the reconstruction for oral cancer, and to examine their associations.</div></div><div><h3>Methods</h3><div>A consecutive sample of 155 oral cancer adults (147 males and 8 females), with or without adjuvants, and surviving 3–30 months after primary microvascular free flaps, were included. The main outcomes were assessed by the Body Image Scale, EORTC QLQ-HN 35, and Mishel's Uncertainty in Illness Scale.</div></div><div><h3>Results</h3><div>Participants reported moderate disturbance in appearance, body as a whole, and sexual attraction, and a moderate-to-low level of EORTC swallowing, speech, and social problems. Less than 20 % have pursued cosmetic surgeries after reconstruction. After adjusting for demographic and clinical factors, poor body image (<em>β</em> = .318), poor speech (<em>β</em> = .198), lower household incomes (<em>β</em> = -.153), and farmers v.s. counterparts were more likely to have higher uncertainty in illness (Adj.R<sup>2</sup> = .347).</div></div><div><h3>Conclusions</h3><div>Along with body image disturbance and swallowing problems, financial burden or work-related stress are significant risk factors for higher uncertainty in illness. Providing supportive care to cope with body image disturbances, swallowing and speech problems, and to improve work or financial status are warranted to help oral cancer survivors to cope with uncertainty in illness after free flaps.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100734"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信